STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIRB) announced today that Presidio Pharmaceuticals, Inc. has elected to return the license rights to the HIV nucleoside reverse transcriptase inhibitor (NRTI) MIV-310, enabling Medivir to transfer the full license to the compound and intellectual property to Beijing Mefuvir Medicinal Technology Co. Ltd., which will develop MIV-310 for therapeutic use against HIV. MIV-310 belongs to the group of polymerase projects which are administered by its subsidiary Medivir HIV Franchise AB.
